Cargando…

Implementation of 4Kscore as a Secondary Test Before Prostate Biopsy: Impact on US Population Trends for Prostate Cancer

Prostate cancer screening using prostate-specific antigen (PSA) reduces prostate cancer mortality at the cost of unnecessary prostate biopsy, overdiagnosis, and overtreatment. Several secondary tests have been developed to restrict biopsy to men at the greatest risk of high-grade disease. 4Kscore is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scuderi, Simone, Tin, Amy, Gandaglia, Giorgio, Stabile, Armando, Montorsi, Francesco, Briganti, Alberto, Vickers, Andrew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Brief Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172694/ https://www.ncbi.nlm.nih.gov/pubmed/37182119 http://dx.doi.org/10.1016/j.euros.2023.03.011

Ejemplares similares

Prostate Cancer: Is There Still a Role for Systematic Biopsies? Yes
por: Gandaglia, Giorgio, et al.
Publicado: (2022)

Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer
por: Gandaglia, Giorgio, et al.
Publicado: (2023)

Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine
por: Fredsøe, Jacob, et al.
Publicado: (2022)

Comment on ‘Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome’
por: Dell'Oglio, Paolo, et al.
Publicado: (2017)

Focal therapy for prostate cancer: what is really needed to move from investigational to valid therapeutic alternative?—a narrative review
por: Pellegrino, Antony, et al.
Publicado: (2022)

An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer
por: Bandini, Marco, et al.
Publicado: (2017)

Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer
por: Punnen, Sanoj, et al.
Publicado: (2018)

Optimum threshold of the 4Kscore for biopsy in men with negative or indeterminate multiparametric magnetic resonance imaging
por: de Almeida S, Ricardo, et al.
Publicado: (2023)

Grade and stage misclassification in intermediate unfavorable‐risk prostate cancer radiotherapy candidates
por: Sorce, Gabriele, et al.
Publicado: (2022)

Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended, of Course
por: Gandaglia, Giorgio, et al.
Publicado: (2022)

Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice
por: Gómez Rivas, Juan, et al.
Publicado: (2022)

Anastomotic leaks and catheter time after salvage robot-assisted radical prostatectomy
por: Bandini, Marco, et al.
Publicado: (2018)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
por: Tzeng, Michael, et al.
Publicado: (2021)

Has the COVID-19 outbreak changed the way we are treating prostate cancer? An EAU – YAU Prostate Cancer Working Group multi-institutional study
por: Zattoni, Fabio, et al.
Publicado: (2021)

Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer?
por: Kim, Sang Jin, et al.
Publicado: (2015)

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures
por: Figiel, Sandy, et al.
Publicado: (2023)

The Clinical Value of Performing an MRI before Prostate Biopsy
por: Choi, Myung Sun, et al.
Publicado: (2011)

Is it safe to continue antithrombotic agents before prostate biopsy?
por: Tanabe, Kuniaki, et al.
Publicado: (2019)

Focal therapy for prostate cancer – index lesion treatment vs. hemiablation. A matter of definition
por: Stabile, Armando, et al.
Publicado: (2019)

The Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend
por: Kim, Hyung-Sang, et al.
Publicado: (2012)

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol
por: Beyer, Katharina, et al.
Publicado: (2021)

Prostatic Enlargement
por: Newton, H. Martyn
Publicado: (1905)

Enlargement of the Prostate
por: Kenrick, W. H.
Publicado: (1906)

A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer
por: Drago, Denise, et al.
Publicado: (2021)

Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy
por: Thaiss, Wolfgang M., et al.
Publicado: (2022)

Trends in Incidence of Metastatic Prostate Cancer in the US
por: Desai, Mihir M., et al.
Publicado: (2022)

Outcomes and Trends of Prostate Biopsy for Prostate Cancer in Chinese Men from 2003 to 2011
por: Na, Rong, et al.
Publicado: (2012)

Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer
por: Bravi, Carlo A., et al.
Publicado: (2022)

Prostate biopsy and fiducial placement in the same sitting- a good option during COVID pandemic as well as in patients on anticoagulants/antiplatelets
por: Sen, Anitha, et al.
Publicado: (2021)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Prostatic Enlargement in Natives
por: Marks, R. J.
Publicado: (1905)

Effectiveness of Bi-Parametric MR/US Fusion Biopsy for Detecting Clinically Significant Prostate Cancer in Prostate Biopsy Naïve Men
por: Kim, Young Joo, et al.
Publicado: (2019)

Imaging modalities in synchronous oligometastatic prostate cancer
por: Futterer, Jurgen J., et al.
Publicado: (2018)

Comparison of MRI/US Fusion Targeted Biopsy and Systematic Biopsy in Biopsy-Naïve Prostate Patients with Elevated Prostate-Specific Antigen: A Diagnostic Study
por: Huang, Chen, et al.
Publicado: (2022)

The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence
por: Bianchi, Lorenzo, et al.
Publicado: (2022)

PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment
por: Bianchi, Lorenzo, et al.
Publicado: (2023)

Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions
por: Zattoni, Fabio, et al.
Publicado: (2023)

Digitate Tumours of the Prostate, Prostatectomy
por: Clark, Somerton
Publicado: (1914)

Enlargement of the Prostate in Natives of India
por: Wanless, W. J.
Publicado: (1906)

Castration for Hypertrophy of the Prostate Gland
Publicado: (1895)

Cannot write session to /tmp/vufind_sessions/sess_kav37tmlmqgl73qouvbb8ehhbu